Entera Bio (ENTX) vs Zura Bio (ZURA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Entera Bio (ENTX) has outperformed Zura Bio (ZURA) over the past year, gaining 6.0% versus a loss of 11.3%. Entera Bio is the larger company by market cap ($462.4 million vs $383.3 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ENTX | ZURA |
|---|---|---|
| Share price | $2.66 | $4.00 |
| Market cap | $462.40M | $383.32M |
| 1-day change | +6.40% | -3.15% |
| YTD return | +37.11% | -23.66% |
| 1-year return | +5.98% | -11.31% |
| 5-year return | -41.15% | — |
| EPS (TTM) | $-0.36 | $-1.12 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.20 | $7.44 |
| 52-week low | $0.91 | $3.15 |
| Distance from 52-week high | -36.67% | -46.24% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +266.54% | +350.00% |
| Average volume | 1.85M | 1.44M |
| Shares outstanding | 173.83M | 95.83M |
| Employees | 20 | 40 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ENTX has outperformed ZURA by 17.3 percentage points over the past year.
About Entera Bio
ENTX stock →Entera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally. It develops EB613, an oral teriparatide, which completed the Phase II clinical trial for the treatment of osteoporosis and Phase I clinical trial for the treatment of stress fractures.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 20 employees
About Zura Bio
ZURA stock →Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States. The company develops Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody engineered to bind and neutralize both IL-17A and BAFF within a single therapeutic molecule, which is in Phase 2 clinical trial development.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 40 employees
ENTX vs ZURA FAQ
Which is bigger, Entera Bio or Zura Bio?
Entera Bio (ENTX) is larger, with a market capitalization of $462.40M compared with $383.32M for Zura Bio (ZURA).
Which stock has performed better over the past year, ENTX or ZURA?
ENTX returned +5.98% over the past 12 months, compared with -11.31% for ZURA (price return, excluding dividends). Past performance does not predict future results.
Are Entera Bio and Zura Bio in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.